A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts
Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Oliver G. Ottmann(Cardiff University), Pierre Fenaux(Saint Louis University Hospital), Suddhasatta Acharyya(Novartis (United States)), Lucien Gazi(Novartis (Switzerland)), Carlos Graux(CHU Dinant Godinne UCL Namur), David Valcárcel(Vall d'Hebron Hospital Universitari), Miklós Egyed(Somogy Megyei Kaposi Mór Oktató Kórház), Mikkael A. Sekeres(University of Miami), Karen Yee(University Health Network), Alan Macwhannell(The Royal Wolverhampton NHS Trust), Reinhard Stauder(Innsbruck Medical University), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Massimo Breccia(Policlinico Umberto I), Nancy Zhu(Alberta Hospital Edmonton), Mahtab Marker(Novartis (United States)), H Salman(Augusta University), Jamie Cavenagh(St Bartholomew's Hospital), Susan Ide(Novartis (United States)), Z Borbényi(University of Szeged), Árpád Illés(University of Debrecen)
Cited by 70
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k